Cross-Sectional Analysis of Peripheral Blood Mononuclear Cells in Lymphopenic and Non-lymphopenic Relapsing-Remitting Multiple Sclerosis Patients Treated with Dimethyl Fumarate.

2021 ◽  
pp. 103003
Author(s):  
Chieh-Hsin Lee ◽  
Bei Jiang ◽  
Maryam Nakhaei-Nejad ◽  
David Barilla ◽  
Gregg Blevins ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Mononuclear Cells ◽  
Dimethyl Fumarate ◽  
Peripheral Blood Mononuclear ◽  
Cross Sectional ◽  
Relapsing Remitting ◽  
Blood Mononuclear Cells ◽  
Multiple Sclerosis Patients ◽  
Sectional Analysis ◽  
Relapsing Remitting Multiple Sclerosis

scholarly journals Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs

2021 ◽  
Vol 11 (8) ◽  
pp. 721
Author(s):  
Afshin Derakhshani ◽  
Zahra Asadzadeh ◽  
Hossein Safarpour ◽  
Patrizia Leone ◽  
Mahdi Abdoli Shadbad ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Mononuclear Cells ◽  
Demyelinating Disease ◽  
Immune Checkpoints ◽  
Peripheral Blood Mononuclear ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis ◽  
The Impact

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS) that is characterized by inflammation which typically results in significant impairment in most patients. Immune checkpoints act as co-stimulatory and co-inhibitory molecules and play a fundamental role in keeping the equilibrium of the immune system. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and Programmed death-ligand 1 (PD-L1), as inhibitory immune checkpoints, participate in terminating the development of numerous autoimmune diseases, including MS. We assessed the CTLA-4 and PD-L1 gene expression in the different cell types of peripheral blood mononuclear cells of MS patients using single-cell RNA-seq data. Additionally, this study outlines how CTLA-4 and PD-L1 expression was altered in the PBMC samples of relapsing-remitting multiple sclerosis (RRMS) patients compared to the healthy group. Finally, it investigates the impact of various MS-related treatments in the CTLA-4 and PD-L1 expression to restrain autoreactive T cells and stop the development of MS autoimmunity.

No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing—remitting multiple sclerosis patients

2010 ◽  
Vol 16 (3) ◽  
pp. 366-369 ◽  
Author(s):  
R. Reuβ ◽  
V. Schreiber ◽  
A. Klein ◽  
C. Infante-Duarte ◽  
M. Filippi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Peripheral Blood Mononuclear Cells ◽  
Chemokine Receptor ◽  
Peripheral Blood ◽  
Mononuclear Cells ◽  
Intercellular Adhesion ◽  
Peripheral Blood Mononuclear ◽  
Relapsing Remitting ◽  
Blood Mononuclear Cells ◽  
Relapsing Remitting Multiple Sclerosis

We investigated the expression of intercellular adhesion molecules ICAM-1 and ICAM-3 on peripheral blood mononuclear cells in a subgroup of 34 patients with relapsing-remitting multiple sclerosis who were treated orally with the chemokine receptor 1 antagonist BX 471 in a 16-week, randomised, double-blind, placebo-controlled phase II study. ICAM-1 and ICAM-3 expression was measured by flow cytometry at different time points during and after therapy and compared using multivariate analysis of variance and non-parametric Mann Whitney test. ICAM-3 expression on CD14 + peripheral blood mononuclear cells was increased in the verum group under therapy, but did not differ significantly between the verum and placebo groups. Most likely, this trend represents a small epiphenomenon only mediated by receptor cross-talk and feedback mechanisms.

Sign in / Sign up

Export Citation Format

Share Document